Workflow
感冒类药品
icon
Search documents
党建引领强担当 监管聚力守药安—新疆沙湾市市监局以党建指导员为纽带护航冬季用药用械安全
Zhong Guo Shi Pin Wang· 2025-12-08 07:00
Core Viewpoint - The Xinjiang Shawan City Market Supervision Administration is implementing a "Party Building Guidance + Law Enforcement Supervision" integration model to enhance the safety of drug and medical device usage during the winter respiratory disease peak season [1] Group 1: Party Building and Regulatory Integration - The administration has appointed party member law enforcement officers as Party Building Guides to work closely with local drug and medical device businesses, promoting the integration of party building and regulatory oversight [1] - These guides serve dual roles as enforcement inspectors and party building counselors, helping businesses improve their party organization and management systems [1] Group 2: Focus on Drug Safety - The initiative emphasizes strict checks on key drug categories such as cold medications and chronic disease treatments, ensuring compliance with regulations regarding procurement, qualifications, storage conditions, and prescription drug sales [1] - The administration plans to increase the frequency of market inspections and intensify efforts to combat illegal activities, aiming to enhance the standardization of drug and medical device businesses [1]
粤万年青股价下跌3.05% 股东减持触及1%比例
Jin Rong Jie· 2025-08-05 17:04
Group 1 - The stock price of Yue Wannianqing closed at 18.42 yuan on August 5, 2025, down 0.58 yuan, a decrease of 3.05% from the previous trading day [1] - The trading volume on that day was 119,714 hands, with a transaction amount of 223 million yuan [1] - The company specializes in the research, production, and sales of traditional Chinese medicine, primarily focusing on cold-related medications [1] Group 2 - In the first quarter of 2025, the company reported operating revenue of 70.81 million yuan and a net loss of 3.44 million yuan [1] - Shareholder Hehe Investment reduced its holdings by 895,000 shares on August 4, decreasing its ownership from 8.22% to 7.66% [1] - The company stated on its investor interaction platform that it currently does not produce or sell any drugs specifically targeting Chikungunya virus [1] Group 3 - On August 5, the net outflow of main funds was 14.56 million yuan, accounting for 0.49% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 8.73 million yuan, representing 0.3% of the circulating market value [1]